Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase 2/3 ...
Andriy Blokhin has 5+ years of professional experience in public accounting, personal investing, and as a senior auditor with Ernst & Young. Thomas J. Brock is a CFA and CPA with more than 20 years of ...
Abstract: We study the transmission properties of a guide consisting of a dielectric rod with rectangular cross section, surrounded by several dielectrics of smaller refractive indices. This guide is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results